Knekt P, Reunanen A, Takkunen B, Aromaa A, Heliovaara M, Hakulinen T: Body iron stores and risk of cancer. Int J Cancer. 1994, 56: 379-392.
Article
CAS
PubMed
Google Scholar
Stevens RG, Grauzard BI, Micozzi MS, Nerishi K, Blumberg BS: Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer. 1994, 56: 364-369.
Article
CAS
PubMed
Google Scholar
Stevens RG, Jones DY, Micozzi MS, Taylor PR: Body iron stores and the risk of cancer. N Engl J Med. 1988, 75: 81-84.
Google Scholar
Nelson RL: Disease risk in hereditary hemochromatosis heterozygotes. In: Hemochromatosis. Genetics, Pathophysiology, Diagnosis, and Treatment. Edited by: Barton JC, Edwards CQ. 2000, Cambridge, Cambridge University Press, 427-432.
Chapter
Google Scholar
Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996, 13: 399-408.
Article
CAS
PubMed
Google Scholar
Dorak MT, Burnett AK, Worwood M, Sproul AM, Gibson BE: The C282Y mutation of HFE is another male-specific risk factor for childhood acute lymphoblastic leukemia. Blood. 1999, 93: 3957-3958.
Google Scholar
Rodriguez-Paris J, Smith M, Mills G, McLarty J, Glass J: The C282Y allele for hemochromatosis is a risk factor for lung cancer in females but not males. Blood. 2003, 102: 11b-
Google Scholar
Martinez di Montemuros F, Tavazzi D, Salsano E, Piepoli T, Pollo B, Fiorelli G, Finocchiaro G: High frequency of the H63D mutation of the hemochromatosis gene (HFE) in malignant gliomas. Neurology. 2001, 57: 1342-
Article
CAS
PubMed
Google Scholar
Bathum L, Christiansen L, Nybo H, Ranberg KA, Gaist D, Jeune B, Petersen NE, Vaupel J, Christensen K: Association of mutations in the hemochromatosis gene with shorter life expectancy. Arch Int Med. 2444, 161: 2441-2001. 10.1001/archinte.161.20.2441.
Article
Google Scholar
Beckman LE, Van Landeghem GF, Sikstrom C, Wahlin A, Markevarn B, Hallmans G, Lenner P, Athlin L, Stenling R, Beckman L: Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis. 1999, 20: 1231-1233. 10.1093/carcin/20.7.1231.
Article
CAS
PubMed
Google Scholar
Beris P, Samii K, Darbellay R, Zoumbos N, Tsoplou P, Kourakli A, Preud'homme C, Fenaux P: Iron overload in patients with sideroblastic anaemia is not related to the presence of the haemochromatosis Cys282Tyr and His63Asp mutations. Br J Haematol. 1999, 104: 97-99. 10.1046/j.1365-2141.1999.01142.x.
Article
CAS
PubMed
Google Scholar
Bottomley SS, Wise PD, Wasson EG, Barton JC: The hemochromatosis of sideroblastic anemias. World Congress on Iron Metabolism (Sorrento). 1999
Google Scholar
Speletas M, Vlachaki E, Papaioannou G, Tzoanopoulos D, Vasilikioti S, Mandala E, Ritis K, Kartalis G, Korantzis I: Prevalence of hemochromatosis gene (HFE) mutations in Greek patients with myelodysplastic syndromes (MDS). Blood. 2001, 98: 276b-
Google Scholar
Gimferrer E, Nomdedeu J, Gich I, Barcelo MJ, Baiget M: Prevalence of hemochromatosis related HFE gene mutations in patients with acute myeloid leukemia. Leuk Res. 1999, 23: 597-598. 10.1016/S0145-2126(99)00043-0.
Article
CAS
PubMed
Google Scholar
MacDonald GA, Tarish J, Whitehall VJ, McCann SJ, Mellick GD, Buttenshaw RL, Johnson AG, Young J, Leggett BA: No evidence of increased risk of colorectal cancer in individuals heterozygous for the Cys282Tyr haemochromatosis mutation. J Gastroenterol Hepatol. 1999, 14: 1188-1191. 10.1046/j.1440-1746.1999.02027.x.
Article
CAS
PubMed
Google Scholar
Barton JC, Shih WWH, Sawada-Hirai R, Acton RT, Harman L, Rivers C, Rothenberg BE: Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis. Blood Cells Mol Dis. 1997, 23: 135-145. 10.1006/bcmd.1997.0129.
Article
CAS
PubMed
Google Scholar
Barton JC, Sawada-Hirai R, Rothenberg BE, Acton RT: Two novel missense HFE mutations (I105T and G93R) and confirmation of the S65C mutation in Alabama hemochromatosis probands. Blood Cells Mol Dis. 1999, 25: 146-154. 10.1006/bcmd.1999.0240.
Article
Google Scholar
Scheuer PJ, Williams R, Muir AR: Hepatic pathology in relatives of patients with hemochromatosis. J Pathol Bacteriol. 1962, 84: 53-63.
Article
CAS
PubMed
Google Scholar
Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA: Practice parameter for hereditary hemochromatosis. Clin Chim Acta. 1996, 245: 139-200. 10.1016/0009-8981(95)06212-2.
Article
CAS
PubMed
Google Scholar
Barton JC, McDonnell SE, Adams PC, Brissot P, Powell LW, Edwards CQ, Cook JD, Kowdley KV, & the Hemochromatosis Management Working Group: Management of hemochromatosis. Ann Intern Med. 1998, 129: 932-939.
Article
CAS
PubMed
Google Scholar
SAS Users Guide, Statistics, Version 6.12. 1997, SAS Institute (Cary)
Woolf B: On estimating the relation between blood groups and disease. Ann Hum Genet. 1955, 19: 251-253.
Article
CAS
PubMed
Google Scholar
Beutler E, Felitti VJ: The C282Y mutation does not shorten lifespan. Arch Int Med. 2002, 162: 1196-1197. 10.1001/archinte.162.10.1196.
Article
Google Scholar
Dorak MT, Burnett AK, Worwood M: Hemochromatosis gene in leukemia and lymphoma. Leuk Lymphoma. 2002, 43: 467-477. 10.1080/10428190290011930.
Article
PubMed
Google Scholar
Waalen J, Nordestgaard BG, Beutler E: Survival of homozygotes for the HFE C282Y hemochromatosis mutation: a meta-analysis. Blood. 2003, 102: 759a-
Google Scholar
van Landeghem GF, Beckman GF, Wahlin A, Markevärn B, Beckman L: Interaction between hemochromatosis and transferrin receptor genes in multiple myeloma. Lancet. 1998, 352: 1285-1286.
Article
CAS
PubMed
Google Scholar
Hannuksela J, Savolainen ER, Koistinen P, Parkkila S: Prevalence of HFE genotypes, C282Y and H63D, in patients with hematologic disorders. Haematologica. 2002, 87: 31-135.
Google Scholar
Andrikovics H, Klein I, Kalmar L, Bors A, Jermendy G, Petri I, Kalasz L, Varadi A, Tordai A: [A new method for molecular testing in the differential diagnosis of hereditary hemochromatosis]. Orvosi Hetilap. 1999, 140: 2517-2522.
CAS
PubMed
Google Scholar
Szakony S, Balogh I, Muszbek L: The frequency of the haemochromatosis C282Y mutation in the ethnic Hungarian and Romany populations of eastern Hungary. Br J Haematol. 1999, 107: 464-465. 10.1046/j.1365-2141.1999.01787.x.
Article
CAS
PubMed
Google Scholar
Barton JC, Bertoli LF: Transfusion iron overload in adults with acute leukemia: manifestations and therapy. Am J Med Sci. 2000, 319: 73-78. 10.1097/00000441-200002000-00001.
Article
CAS
PubMed
Google Scholar
Parkkila S, Niemilä O, Savolainen E-R, Koistinen P: HFE mutations do not account for transfusional iron overload in patients with acute myeloid leukemia. Transfusion. 2001, 41: 828-831. 10.1046/j.1537-2995.2001.41060828.x.
Article
CAS
PubMed
Google Scholar
Shaheen NJ, Silverman LM, Keku T, Lawrence LB, Rohlfs EM, Martin CF, Galanko J, Sandler RS: Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst. 2003, 95: 154-159. 10.1093/jnci/95.2.154.
Article
CAS
PubMed
Google Scholar
Bomford A, Williams R: Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med. 1976, 180: 611-623.
Google Scholar
Ammann RW, Muller E, Bansky J, Schuler G, Hacki WH: High incidence of extrahepatic carcinomas in idiopathic haemochromatosis. Scand J Gastroenterol. 1980, 15: 733-736.
Article
CAS
PubMed
Google Scholar
Tiniakos G, Williams R: Cirrhotic process, liver cell carcinoma and extrahepatic malignant tumors in idiopathic haemochromatosis. Study of 71 patients treated with venesection therapy. Appl Pathol. 1998, 6: 128-138.
Google Scholar
Adams PC, Speechley M, Kertesz AE: Long-term survival analysis in hereditary hemochromatosis. Gastroenterology. 1991, 101: 368-372.
Article
CAS
PubMed
Google Scholar
Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, Fraumeni JF: Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer. 1995, 60: 160-162.
Article
CAS
PubMed
Google Scholar
Barton JC, Barton NH, Alford TJ: Diagnosis of hemochromatosis in a community hospital. Am J Med. 1997, 103: 498-503. 10.1016/S0002-9343(97)00276-3.
Article
CAS
PubMed
Google Scholar
Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, Fargion S: Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology. 2001, 33: 647-651. 10.1053/jhep.2001.22506.
Article
CAS
PubMed
Google Scholar
Hebert BJ, Alonto AM, Mehdi S: Incidence and relationship of non-hepatocellular malignancies in patients with hemochromatosis. Blood. 2001, 98: 5b-
Google Scholar
Bradbear RA, Bain C, Siskind V, Schofield FD, Webb S, Axelsen EM, Halliday JW, Bassett ML, Powell LW: Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic diseases. J Natl Cancer Inst. 1985, 75: 81-84.
CAS
PubMed
Google Scholar
Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G: Survival and causes of death in cirrhotic and non-cirrhotic patients with primary hemochromatosis. N Engl J Med. 1985, 313: 1256-1262.
Article
CAS
PubMed
Google Scholar
Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, Fraquelli M, Bianchi PA, Fiorelli G, Conte D: Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology. 1992, 15: 655-659.
Article
CAS
PubMed
Google Scholar
Deugnier Y, Loreal O: Iron as a carcinogen. In: Hemochromatosis. Genetics, Pathophysiology, Diagnosis, and Treatment. Edited by: Barton JC, Edwards CQ. 2000, Cambridge, Cambridge University Press, 239-249.
Chapter
Google Scholar
Blanc J-F, De Ledinghem V, Bernard P-H, de Verneuil H, Winnock M, Le Bail B, Carles J, Saric J, Balabaud C, Bioulac-Sage P: Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J Hepatol. 2000, 32: 805-811. 10.1016/S0168-8278(00)80250-0.
Article
CAS
PubMed
Google Scholar
Racchi O, Mangerini R, Rapezzi D, Gaetani GF, Nobile MT, Picciotto A, Ferrari AM: Mutations of the HFE gene and the risk of hepatocellular carcinoma. Blood Cells Mol Dis. 1999, 25: 350-353. 10.1006/bcmd.1999.0263.
Article
CAS
PubMed
Google Scholar
Dorak MT, Lawson T, Machulla HK, Darke C, Mills KI, Burnett AK: Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia. Blood. 1999, 94: 694-700.
CAS
PubMed
Google Scholar
Barton JC, Acton RT: Transferrin saturation phenotype and HFE genotype screening for hemochromatosis and primary iron overload: predictions from a model based on national, racial, and ethnic group composition in central Alabama. Genet Test. 2000, 4: 199-206. 10.1089/10906570050114911.
Article
CAS
PubMed
Google Scholar
Merryweather-Clarke AT, Pointon JJ, Rochette J, Robson KJH: Geography of HFE C282Y and H63D mutations. Genet Test. 2000, 4: 183-198. 10.1089/10906570050114902.
Article
CAS
PubMed
Google Scholar
Burke W, Thomson E, Khoury MJ, McDonnell SM, Press N, Adams PC, Barton JC, Beutler E, Brittenham G, Buchanan A, Clayton EW, Cogswell ME, Meslin EM, Motulsky AG, Powell LW, Sigal E, Wilfond BS, Collins FS: Hemochromatosis: gene discovery and its implications for population-based screening. J Am Med Assoc. 1998, 280: 172-178. 10.1001/jama.280.2.172.
Article
CAS
Google Scholar
MacLaren CE, Gordeuk VR, Looker AC, Hasselblad V, Edwards CQ, Griffen LM, Kushner JP, Brittenham GM: Prevalence of heterozygotes for hemochromatosis in the white population of the United States. Blood. 1995, 86: 2021-2027.
Google Scholar
Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP: Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med. 1996, 335: 1799-1805. 10.1056/NEJM199612123352403.
Article
CAS
PubMed
Google Scholar
Nelson RL, Davis FG, Persky V, Becker E: Benign and malignant disease risk in hereditary hemochromatosis heterozygotes. Cancer. 1995, 76: 875-879.
Article
CAS
PubMed
Google Scholar
Murphy CC, Go RCP, Acton RT, Barger BO, Roseman JM: Genetic analysis of multiply affected families with insulin dependent diabetes mellitus (IDDM) probands. Hum Hered. 1983, 33: 344-356.
Article
CAS
PubMed
Google Scholar
Schacht LE, Gershowitz H: Frequency of extra-marital children as determined by blood groups. In: Proceedings of the Second International Congress on Human Genetics. Edited by: Gedda L. 1963, Rome, G. Mendel, 894-897.
Google Scholar
Hussain SP, Raja K, Amstad PA, Sawyer M, Trudel LJ, Wogan GN, Hofseth LJ, Shields PG, Billiar TR, Trautwein C, Hohler T, Galle PR, Phillips DH, Markin R, Marrogi AJ, Harris CC: Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: oxyradical overload diseases. Proc Natl Acad Sci USA. 2000, 97: 12770-12775. 10.1073/pnas.220416097.
Article
CAS
PubMed
PubMed Central
Google Scholar
Green R, Esparza I, Schreiber R: Iron inhibits the non-specific tumoricidal activity of macrophages: a possible contributory mechanism for neoplasia in hemochromatosis. Ann N Y Acad Sci. 1988, 526: 310-309.
Article
Google Scholar
Huot AE, Gundel RM, Hacker MP: Effect of erythrocytes on alveloar macrophage cytostatic activity induced by bleomycin lung damage in rats. Cancer Res. 1990, 50: 2351-2355.
CAS
PubMed
Google Scholar
Brock JH: Iron in infection, immunity, inflammation and neoplasia. In: Iron Metabolism in Health and Disease. Edited by: Brock JH, Halliday JW, Pippard J, Powell LW. 1994, London, W.B. Sanders Company Ltd, 354-389.
Google Scholar
Ikuta K, Fujimoto Y, Suzuki Y, Tanaka K, Saito H, Ohhira M, Sasaki K, Kohgo Y: Overexpression of hemochromatosis protein, HFE, alters transferrin recycling process in human hepatoma cells. Biochim Biophys Acta. 2000, 1496: 221-231. 10.1016/S0167-4889(00)00016-1.
Article
CAS
PubMed
Google Scholar
Porto G, de Sousa M: Variation of hemochromatosis prevalence and genotype in national groups. In: Hemochromatosis. Genetics, Pathophysiology, Diagnosis, and Treatment. Edited by: Barton JC, Edwards CQ. 2000, Cambridge, Cambridge University Press, 51-62.
Chapter
Google Scholar
Acton RT, Barger BO: The potential use of HLA to predict risk of malignant diseases and outcome of therapy. In: Pediatric Oncology. Edited by: Humphrey GB, Dehner LP, Grindey GB, Acton RT. 1981, The Hague, Martinus Nijhoff Publishers, 1: 47-77.
Google Scholar
Braun WE: HLA and Disease: A Comprehensive Review. 1979, Boca Raton, CRC Press, 79-86.
Google Scholar
Wang SS, Wheeler CS, Hildesheim A, Schiffman M, Herrero R, Bratti MC, Sherman ME, Alfaro M, Hutchinson ML, Morales J, Lorincz A, Burk RD, Carrington M, Erlich HA, Apple RJ: Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: Results from a population-based study in Costa Rica. J Infect Dis. 2001, 184: 1310-1314. 10.1086/324209.
Article
CAS
PubMed
Google Scholar